Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (XTRA:LLY) from Buy to Reduce. As of April 24, 2025, the average one-year price target for Eli Lilly and is ...

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC (LON:HSBA) noted, "We are ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (WBAG:LLYC) from Buy to Reduce. There are 5,524 funds or institutions reporting positions in Eli Lilly and.

Eli Lilly (LLY), on the other hand, saw a double downgrade from HSBC analysts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.